Open AccessA phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
Author(s) -
Nancy U. Lin,
Eric P. Winer,
Duncan Wheatley,
Lisa A. Carey,
Stephen Houston,
David S. Mendelson,
Pamela N. Münster,
Laurie Frakes,
Steven Kelly,
Agustin A. García,
Susan Cleator,
Martina Uttenreuther-Fischer,
Hilary Jones,
Sven Wind,
Richard Vinisko,
Tamas Hickish
Publication year - 2012
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/b53z-jj28
Subject(s) - afatinib , trastuzumab , medicine , breast cancer , oncology , metastatic breast cancer , erbb , cancer , cancer research , epidermal growth factor receptor , erlotinib